Respiratory muscle strength in volleyball players suffered from COVID-19

Çelik, Zeliha; Güzel, Nevin Atalay; Kafa, Nihan; Köktürk, Nurdan

doi:10.1007/s11845-021-02849-z

Cited by 20 publications

(30 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Of the 43 studies and 11 518 infected athletes included in this systematic review, the median number (IQR) of participants per study was 26 (15–101). The included studies were conducted in Argentina,15 Australia,16 Brazil,1 17 Denmark,18 Finland,19 Germany,20–23 Hungary,8 24 25 Italy,9 26–31 Poland,14 Qatar,2 Russia,32 Serbia,33 Turkey,34 UK35 36 and USA 3 6 7 37–47. One study was a multicentre collaboration led by researchers in South Africa,48 and one study was conducted across different countries in Europe 49…”

Section: Resultsmentioning

confidence: 99%

“…Eleven (25%) studies included only male athletes,2 9 15 18 19 21 22 29 33 36 49 2 (5%) studies included only female athletes32 34 and 22 (51%) studies included both male and female athletes 1 3 6 8 14 16 24–28 35 37–39 41–44 46–48. Eight (19%) studies did not report data on sex 7 17 20 23 30 31 40 45.…”

Section: Resultsmentioning

confidence: 99%

“…Fourteen studies did not report the age of participants 2 7 9 18 22 23 31 32 36 37 40 44 45 49. Two studies included only amateur athletes,19 30 12 studies included only college/university athletes,3 6 37–40 42–47 1 study included both collegiate and amateur athletes27 and 23 studies included only professional/elite athletes 1 2 7–9 14–16 18 21 22 24–26 29 31–36 41 49. Three studies included both professional and non-professional athletes,23 28 48 and 1 study included professional, college and amateur athletes 17.…”

Section: Resultsmentioning

confidence: 99%

“…Fifteen studies reported on infections among athletes following reopening or during sport competitions,1 2 15 16 18–20 22 23 26 29 31 32 36 49 9 studies reported on infections following return-to-play/campus protocols,7 27 28 38–40 43 44 46 11 studies included analyses of previously collected data (ie, medical records),6 9 14 21 35 37 41 42 45 47 48 7 studies enrolled previously infected athletes3 8 24 25 30 33 34 and 1 study was an online survey 17. An overview of the included studies is provided in online supplemental table 3.…”

Section: Resultsmentioning

confidence: 99%

“…Thirty-five (n=5709) studies provided data of asymptomatic athletes, and 26 (n=5091) of these also reported data on symptomatic athletes (ie, mild, moderate, severe). Eight studies did not describe the disease severity and were not included in the pooled event rate estimate 7 9 19 23 34 37 42 48. Asymptomatic and paucisymptomatic athletes from the study by Martinez et al 41 were grouped as asymptomatic in this review.…”

Section: Resultsmentioning

confidence: 99%

See 4 more Smart Citations

Acute and post-acute COVID-19 presentations in athletes: a systematic review and meta-analysis

et al. 2022

View full text Add to dashboard Cite

ObjectiveTo describe acute/postacute COVID-19 presentations in athletes.DesignSystematic review and meta-analysis.Data sourcesThe search was conducted in four databases (MEDLINE, EMBASE, SCOPUS, SPORTDiscus) and restricted to studies published from 2019 to 6 January 2022.Eligibility criteria for selecting studiesStudies were required to (1) include professional, amateur or collegiate/university athletes with COVID-19; (2) present data on acute/postacute COVID-19 symptoms and (3) have an observational design. Risk of bias was assessed using the Joanna Briggs Institute Critical Appraisal tools.Results43 studies with 11 518 athletes were included. For acute presentation, the pooled event rates for asymptomatic and severe COVID-19 were 25.5% (95% CI: 21.1% to 30.5%) and 1.3% (95% CI: 0.7% to 2.3%), respectively. For postacute presentations, the pooled estimate of persistent symptoms was 8.3% (95% CI: 3.8% to 17.0%). Pooled estimate for myocardial involvement was 5.0% (95% CI: 2.5% to 9.8%) in athletes undergoing any cardiac testing, and 2.5% (95% CI: 1.0% to 5.8%) in athletes undergoing MRI, although clinical symptoms were not characterised. None of the studies with a control group (eg, non-infected athletes) could confirm a causal relationship between COVID-19 and myocardial involvement.ConclusionThis broad characterisation of COVID-19 presentations in athletes indicates that ~94% exhibited mild or no acute symptoms. The available evidence did not confirm a causal relationship between COVID-19 and myocardial involvement. A small proportion of athletes experienced persistent symptoms while recovering from infection, which were mostly mild in nature, but could affect return-to-play decisions and timing.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Acute and post-acute COVID-19 presentations in athletes: a systematic review and meta-analysis

et al. 2022

View full text Add to dashboard Cite

show abstract

A follow‐up study on respiratory outcomes, quality of life and performance perception of SARS‐CoV‐2 primary and reinfection in elite athletes: A 9‐month prospective study

Karaduman,

Bostancı,

Bilgiç

2024

European Journal of Sport Science

View full text Add to dashboard Cite

The prolonged consequences of SARS‐CoV‐2 on young elite athletes recovering from primary and reinfection are unclear. This study aimed to assess inspiratory/expiratory muscle strength and respiratory function at the time of spontaneous recovery at 3, 6, and 9 months after SARS‐CoV‐2 primary and reinfection in elite athletes. The study enrolled 25 elite male judoists, including 11 primary infection cases, five reinfection cases, and nine controls from the Türkiye Olympic Preparation Center. Inspiratory/expiratory muscle strength and respiratory function were measured, including maximal inspiratory pressure (MIP), maximal expiratory pressure (MEP), forced expiratory volume in 1 s (FEV1), forced vital capacity (FVC), FEV1/FVC, and peak expiratory flow (PEF) before and up to 9 months after SARS‐CoV‐2 infection in the early pre‐competition preparation phases. The most common symptoms reported by reinfection cases were fatigue (80%), dyspnea (60%), and muscle/joint pain (60%), while primary infection cases reported fatigue (73%), muscle/joint pain (45%), and headache (45%). MIP decreased by −14% and MEP decreased by −13% following the SARS‐CoV‐2 infection in reinfection cases. Likewise, FEV1 and FVC decreased by −5% and −8%, respectively; consequently, FEV1/FVC increased by 3%. Inspiratory/expiratory muscle strength and respiratory function improved rapidly after 9 months of SARS‐CoV‐2 infection in primary cases, whereas dysfunction persisted in reinfection cases. PEF was unaffected throughout the 9‐month follow‐up period. Reinfection may lead to further alterations in respiratory system relative to the primary infection, with a suspected restrictive pattern that remains dysfunctional in the third month; however, it improves significantly during a 9‐month follow‐up period.

show abstract

Can inspiratory muscle training benefit patients with COVID‐19? A systematic review and meta‐analysis

Chen,

Liu,

Tong

2023

Journal of Medical Virology

View full text Add to dashboard Cite

The possible benefits of inspiratory muscle training (IMT) on mechanical and clinical outcomes in patients with Coronavirus disease‐2019 (COVID‐19) remain controversial. We conducted a meta‐analysis to evaluate the effect of IMT in the rehabilitation strategy of patients with COVID‐19. The Pubmed, Embase, Web of Science (WOS), and Cochrane Central Register of Controlled Trials (CENTRAL) were searched to identify trials evaluating the efficacy of IMT in the treatment of patients with COVID‐19. The primary outcome included change from baseline of VO2max, maximal inspiratory pressure (PImax), 6‐min walk test(6MWT), forced expiratory volume in the first second predicted (FEV1%pred), and quality of life (QOL). Six studies with 349 participants were analyzed. Significant improvements were found in change from baseline of VO2max (MD: 4.54, 95% confidence interval [CI]: 1.79–7.30, Z = 3. 32, I2 = 0, p = 0.001), PImax (MD: 21.43, 95% CI: 1.33–41.52, Z = 2.09, I2 = 90%, p = 0.04), 6MWD (MD: 40.13, 95% CI: 24.92–55.35, Z = 5.17, I2 = 0, p < 0.00001) and FEV1%pred (MD: 8.73, 95% CI 3.07–14.39, Z = 3.02, p = 0.002) while no statistical improvements were found in QOL (SMD: 0.70, 95% CI: 0.37–1.03, Z = 4.15, I2 = 89% p = 0.32) between IMT group and control group. The application of IMT might elicit mechanical and clinical improvement in patients with COVID‐19. IMT could be recommended as an effective strategy of pulmonary rehabilitation for COVID‐19. However, the proper timing, optimal duration, as well as appropriate frequency and intensity of IMT remain uncertain and further studies are needed.

show abstract

Respiratory muscle strength in volleyball players suffered from COVID-19

Cited by 20 publications

References 30 publications

Acute and post-acute COVID-19 presentations in athletes: a systematic review and meta-analysis

Acute and post-acute COVID-19 presentations in athletes: a systematic review and meta-analysis

A follow‐up study on respiratory outcomes, quality of life and performance perception of SARS‐CoV‐2 primary and reinfection in elite athletes: A 9‐month prospective study

Can inspiratory muscle training benefit patients with COVID‐19? A systematic review and meta‐analysis

Contact Info

Product

Resources

About